Top News
Adding Chemo to Immunotherapy Improves PFS, Not OS, in Non-Small Cell Lung Cancer
Sulfur Microbial Diet May Increase Risk for Colorectal Cancer
Moderna to Test COVID-19 Booster Candidates Against Omicron Variant
Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Annual Mammography Not Cost-Effective Beyond 75 Years
30 Percent of Hospital-Based Health Care Personnel Unvaccinated
KRd Plus ASCT Outperforms Other Carfilzomib-Based Regimens in Newly Diagnosed Multiple Myeloma
Cytalux Approved to Detect Ovarian Cancer Lesions During Surgery
Thanksgiving Weekend Brought New COVID-19 Concerns: The Omicron Variant
Livtencity Approved for Post-Transplant Cytomegalovirus Infection
RSNA: CT Imaging for Cancer Down During COVID-19 Peak in 2020
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Controversy Prompts Another Update to NCCN Guidelines for Prostate Cancer
After physicians voiced concerns about an active surveillance recommendation, the NCCN panel revised the guidelines. -
COVID-19 Vaccine Boosters Appear Effective in Patients With Thoracic Cancer
Seroconversion was observed in 89% of patients who received a third vaccine dose. -
Daytime Infusions of Immunotherapy Tied to Better Survival in Advanced Melanoma
Receiving at least 20% of infusions after 4:30 pm was associated with shorter survival. -
Parents Report Challenging Relationships With Pediatric Oncology Clinicians
Asian parents were more likely to report challenging relationships. -
Men and Women Differ in Their Refusal of Breast Cancer Treatments
The odds of refusing hormone therapy, surgery, and radiation differed by sex. -
Digital Symptom Monitoring Can Improve Outcomes of Cancer Care
Patients experienced clinically meaningful benefits at various time points. -
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma. -
Treatment Sequence Impacts Survival in BRAF-Mutant Metastatic Melanoma
The 2-year overall survival rate was higher for patients who started treatment with nivolumab-ipilimumab than for those who started with dabrafenib-trametinib. -
Adding Ibrutinib to R-CHOP Doubles EFS in 2 Subgroups of Diffuse Large B-Cell Lymphoma
Younger patients with the MCD and N1 subtypes of DLBCL had 3-year event-free survival rates of 100% when they received ibrutinib plus R-CHOP.
More Features
Genetic Differences May Partly Explain Racial/Ethnic Disparities in Early-Onset Colorectal Cancer
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
Long-Term Benefit With Abemaciclib in High-Risk Early Breast Cancer
The benefit was maintained beyond the 2-year treatment period.
Docs Disagree With Update to NCCN Guidelines for Prostate Cancer
An update to active surveillance recommendations has some physicians concerned.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
- Loading...
Loading...
Loading... 
Loading...